EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat lung cancer with liver metastases
Disease control Not yet recruitingThis phase 2 trial tests whether combining SKB264 (a chemotherapy) with anlotinib (a targeted therapy) can shrink tumors and control disease in people with advanced non-small cell lung cancer that has spread to the liver and stopped responding to standard EGFR-targeted drugs. Abo…
Matched conditions: EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Lung cancer Drug's journey through the body tracked in tiny trial
Knowledge-focused Not yet recruitingThis early-stage study will give 8 healthy Chinese men a single dose of the experimental lung cancer drug zorifertinib, which has been tagged with a tiny amount of radioactivity. By collecting blood, urine, and stool samples over two weeks, researchers will track exactly how the …
Matched conditions: EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC